Evaluating the Changing CDMO Landscape

October 11, 2019
Pharmaceutical Technology Editors

During the first day of CPhI Worldwide in Frankfurt, Germany, a panel of experts will be discussing the evolution of CDMOs in the shifting therapeutic landscape.

During the first day of CPhI Worldwide in Frankfurt, Germany (Tuesday, Nov. 5, 2019), a panel of experts will be discussing the evolution of contract development and manufacturing organizations (CDMOs) in the shifting therapeutic landscape.

In the Pharma Insight Briefings session, which is set to take place at 10:30 am until 11:40 am in hall 12.0 stand 120D40, some of the key questions facing CDMOs will be broached. Topics for consideration will include whether the ‘one-stop-shop’ concept is no longer applicable, the impact of M&A activities as well as consolidation in the industry, and flexible manufacturing approaches. 

The panel of experts will be Peter Bigelow (xCell Strategic Consulting), Daniel Bourgin (Dr. Reddy’s Custom Pharma Services), Bikash Chatterjee (Pharmatech Associates), Anil Kane (Patheon, part of Thermo Fisher Scientific), Jim Miller (founder and former president, PharmSource), Peter Shapiro (PharmSource), Jeremie Trochu (Catalent), and Ganesh Vaidyanathan (Dr. Reddy’s Custom Pharma Services).

Exploring Trends in Contract ManufacturingTuesday Nov. 5, 2019 10:30–11:40 ICSE Theatre (120D40)